TW202214608A - 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 - Google Patents

稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 Download PDF

Info

Publication number
TW202214608A
TW202214608A TW110126621A TW110126621A TW202214608A TW 202214608 A TW202214608 A TW 202214608A TW 110126621 A TW110126621 A TW 110126621A TW 110126621 A TW110126621 A TW 110126621A TW 202214608 A TW202214608 A TW 202214608A
Authority
TW
Taiwan
Prior art keywords
alkyl
cancer
cycloalkyl
haloalkyl
heterocyclyl
Prior art date
Application number
TW110126621A
Other languages
English (en)
Chinese (zh)
Inventor
李心
陳陽
王斌
賀峰
陶維康
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202214608A publication Critical patent/TW202214608A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110126621A 2020-07-20 2021-07-20 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 TW202214608A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010701561 2020-07-20
CN202010701561.X 2020-07-20
CN202011495424.1 2020-12-17
CN202011495424 2020-12-17

Publications (1)

Publication Number Publication Date
TW202214608A true TW202214608A (zh) 2022-04-16

Family

ID=79728964

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110126621A TW202214608A (zh) 2020-07-20 2021-07-20 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用

Country Status (2)

Country Link
TW (1) TW202214608A (fr)
WO (1) WO2022017339A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
WO2020146613A1 (fr) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
BR112022012106A2 (pt) 2019-12-20 2022-09-20 Mirati Therapeutics Inc Inibidores de sos1
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
WO2023280317A1 (fr) * 2021-07-09 2023-01-12 南京明德新药研发有限公司 Composé benzylamino tricyclique et son utilisation
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
WO2023135260A1 (fr) 2022-01-14 2023-07-20 Jazz Pharmaceuticals Ireland Limited Nouveaux phtalazines à substitution amine et dérivés utilisés comme inhibiteurs de sos1
GB202203976D0 (en) * 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
CN114621186A (zh) * 2022-05-12 2022-06-14 上海维申医药有限公司 作为ras信号通路调控剂的杂环化合物
WO2024022507A1 (fr) * 2022-07-29 2024-02-01 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un inhibiteur de kras g12d
WO2024074827A1 (fr) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited Nouveaux traitements de la douleur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
LT3558955T (lt) * 2016-12-22 2021-11-10 Amgen Inc. Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui
EP3878850A1 (fr) * 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
BR112022012106A2 (pt) * 2019-12-20 2022-09-20 Mirati Therapeutics Inc Inibidores de sos1

Also Published As

Publication number Publication date
WO2022017339A1 (fr) 2022-01-27

Similar Documents

Publication Publication Date Title
TW202214608A (zh) 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用
WO2020073949A1 (fr) Régulateur de dérivés hétéroaromatiques contenant de l'azote, procédé de préparation associé et utilisation correspondante
TW202144340A (zh) 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
TW202115042A (zh) 芳基磷氧化物類衍生物抑制劑、其製備方法和應用
TW202144338A (zh) 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
TW202214639A (zh) 吡啶酮并嘧啶類衍生物、其製備方法及其在醫藥上的應用
TW201518278A (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
WO2021249475A1 (fr) Dérivé de quinazoline condensé, son procédé de préparation et son application en médecine
WO2022247816A1 (fr) Composé hétérocyclique contenant de l'azote, son procédé de préparation et son application dans des médicaments
TWI826819B (zh) 一種作為ｂｔｋ抑制劑的化合物及其製備方法與用途
TW202128690A (zh) 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2021197452A1 (fr) Forme cristalline d'un alcali libre de dérivés aromatiques contenant de l'azote
TW202328100A (zh) 含氮雜環類衍生物抑制劑、其製備方法和應用
TW202144353A (zh) 氮呯類稠環化合物及其醫藥用途
TW202140495A (zh) 三環四氫異喹啉類衍生物、其製備方法及其在醫藥上的應用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
TW202106693A (zh) 吲哚類大環衍生物、其製備方法及其在醫藥上的應用
WO2022100738A1 (fr) Forme cristalline d'une base libre d'inhibiteur contenant un dérivé à noyau bicyclique, procédé de préparation et utilisation de la forme cristalline
TW202321241A (zh) 嘧啶或吡啶衍生物及其製備方法和在藥學上的應用
TW202214642A (zh) 咪唑并嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
WO2022161447A1 (fr) Composé dicarboxamide, son procédé de préparation et son utilisation pharmaceutique
WO2024022286A1 (fr) Inhibiteur d'egfr macrocyclique, son procédé de préparation et son utilisation pharmaceutique
WO2024131827A1 (fr) Inhibiteurs de kras g12d et leurs utilisations